Masimo Corporation (MASI) was Reiterated by Wedbush to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 57 from a previous price target of $51 . Wedbush advised their investors in a research report released on May 5, 2016.
Many Wall Street Analysts have commented on Masimo Corporation. Masimo Corporation was Upgraded by Piper Jaffray to ” Overweight” on May 5, 2016.
On the company’s financial health, Masimo Corporation reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.43. The company had revenue of $171.20 million for the quarter, compared to analysts expectations of $165.28 million. The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 EPS.
Masimo Corporation closed down -0.05 points or -0.12% at $42.44 with 3,39,060 shares getting traded on Wednesday. Post opening the session at $42.39, the shares hit an intraday low of $42.01 and an intraday high of $42.78 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 29, 2016, Paul Jansen (EVP, Bus Dev) sold 10,000 shares at $44.88 per share price. According to the SEC, on Mar 23, 2016, Yongsam Lee (EVP & CIO) sold 96,000 shares at $39.97 per share price. On Mar 17, 2016, Raad Mark De (EVP & Chief Financial Officer) sold 40,000 shares at $39.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Masimo Corporation is a global medical technology company that develops manufactures and markets non-invasive patient monitoring products. The Company’s core business is measure-through-motion and low-perfusion pulse oximetry monitoring known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive optical blood constituent monitoring optical organ oximetry monitoring electrical brain function monitoring acoustic respiration monitoring and optical gas monitoring. In addition the Company offers Root patient monitoring and connectivity platform the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. The Company also has the Patient SafetyNet remote patient surveillance monitoring system which allows up to 80 patients to be monitored simultaneously through a central station or remotely by care providers through their pagers or smart phones.